

M. Robert¹, A.M. Carceller¹, A.-M. Demers^{2,3}, M. N Dao⁴, O. Dobrescu¹, J.-F. Chicoine³, M. Libman⁵, T. Fortin¹, M.H. Lebel³

¹Service de Pédiatrie, ²Département de Microbiologie et Immunologie, ³Service des Maladies Infectieuses, CHU Sainte-Justine, Université de Montréal.


⁴National Reference Centre for Parasitology and ⁵Centre for Tropical Diseases, McGill University, Montreal, Canada.

Background and Objective

Foreign-born children often harbour intestinal parasites. We evaluated the prevalence of *Strongyloides stercoralis* (SS) infection in children immigrating to Canada.

REvised ABSTRACT

Figure 1



Methods

- Prospective cohort study
- Immigrant Health Clinic and Tuberculosis Clinic of CHU Sainte-Justine, a paediatric tertiary care center in Montreal, Canada
- From 2009/11 to 2010/06
- Demographic information, growth parameters and laboratory screening tests including SS serology (enzyme immunoassay) and 3 stool specimens for ova and parasites exam were gathered.
- National Center for Health Statistics standardized growth charts^{1,2} were used.
- Region of origin was categorized according to the World Health Organization groupings.³
- Data compilation and analysis were realized with Microsoft Excel Office XP and SPSS software.



© UNICEF/NYHQ2010-2803/Asselin

- *Ancylostoma duodenale*, *Ascaris lumbricoides*, *Dientamoeba fragilis*, *Entamoeba histolytica*, *Enterobius vermicularis*, *Giardia lamblia*, *Hymenolepsis nana*, *Schistosoma mansoni*, *Strongyloides stercoralis* and *Trichuris trichiura* were considered to be pathogenic, while *Blastocystis hominis*, *Chilomastix mesnili*, *Endolimax nana*, *Entamoeba coli*, *Entamoeba dispar*, *Entamoeba hartmanni* and *Iodamoeba buetschlii* were considered to be non-pathogenic.

Table 1 Demographic Information and Growth Parameters

	Positive Test for SS N=18	Negative Test for SS N=218
Gender (female); N (%)	13 (72.2)	113 (51.8)
Age (years)		
Average ± SD	4.8 ± 2.9	7.0 ± 4.8
Median and Ranges	4.4 [2.8-15.8]	5.7 [0.2-18.7]
Age ≤ 5 years		
N (%)	14 (77.8)	96 (44.0)
Average ± SD	3.9 ± 0.7	2.6 ± 1.3
Median and Ranges	3.7 [2.8-5.0]	2.6 [0.2-5.0]
Delay between arrival and evaluation (months)		
Average ± SD	16.0 ± 12.4	13.1 ± 14.4
Median and Ranges	13.8 [8.9-64.4]	7.2 [0-58.4]
Origin		
Americas; N	16	108
Haïti; N (%)	16 (88.9)	88 (40.4)
Africa; N (%)	1 (5.6)	44 (20.2)
East Asia/Western Pacific; N (%)	0	33 (15.1)
Mediterranean/Middle East; N (%)	0	23 (10.6)
Southeast Asia; N (%)	1 (5.6)	10 (4.6)
Immigration Status		
Permanent residents; N (%)	5 (27.8)	132 (60.6)
Temporary residents; N (%)	13 (72.2)	63 (28.9)
Refugees or Asylum seekers; N (%)	0	23 (10.6)
Weight <5% Percentile; N (%)	5 (27.8)	30/217 (13.8)
Height <5% Percentile; N (%)	8/15 (53.3)	25/217 (11.5)
Head Circumference <5% Percentile; N (%)	3/5 (60.0)	11/44 (25.0)

Table 3 Description of positive cases of *Strongyloides stercoralis*

Cases	Gender	Age (years)	Country	Growth	Eosinophil Count ≥500 cell/mm ³	Stool parasites	SS serology*	Treatment
1	F	5	Haïti	N	200	Giardia	0.30	Metronidazole, Ivermectin
2	M	5	Haïti	Weight < 5% Height < 5%	1900	Giardia	0.42	Metronidazole, Ivermectin
3	M	5	Haïti	N	2900	Giardia, Blastocystis hominis	0.33	Metronidazole, Ivermectin
4	F	6	Ghana	N	400	NS	0.56	Ivermectin
5	F	5	Haïti	Height < 5%	1900	negative	1.21	Metronidazole, Ivermectin
6	M	4	Haïti	Height < 5%	3800	Hymenolepsis nana	0.93	Metronidazole, Ivermectin, Praziquantel
7	M	3	Haïti	Weight < 5% Height < 5%	1400	negative	1.39	Ivermectin
8	F	3	Haïti	N	1800	Multiple ⁴ with SS	2.88	Ivermectin
9	F	4	Haïti	Weight < 5%	1500	NS	1.97	Metronidazole, Ivermectin
10	M	3	Haïti	HC < 5%	1200	Multiple ² with SS	1.59	Ivermectin, Praziquantel
11	F	5	Haïti	HC < 5%	1600	Multiple ³	0.81	Metronidazole, Ivermectin, Praziquantel
12	F	3	Haïti	N	2500	Multiple ⁴ with SS	1.05	Ivermectin
13	F	4	Haïti	Height < 5%	600	Multiple ⁵	0.88	Ivermectin, Praziquantel
14	F	5	Haïti	Weight < 5% Height < 5%	600	Multiple ⁶ with SS	0.08	Metronidazole, Ivermectin, Mebendazole
15	F	4	Haïti	Height < 5%	500	Multiple ⁷	0.29	Ivermectin, Praziquantel
16	F	3	Haïti	Weight < 5% Height < 5% HC < 5%	2400	NS	0.24	Metronidazole, Ivermectin
17	F	16	Haïti	N	0	Endolimax nana	0.27	Mebendazole, Albendazole, Paromomycin
18	F	5	Bangladesh	N	200	Multiple ⁸	0.22	Mebendazole, Albendazole, Paromomycin

* Strongyloides serology: M: male
Negative (<0.20); NS: no samples
Doubtful [0.20-0.29]; HC: head circumference

Positive (>0.30); F: female

Multiple Parasites:
1. Blastocystis hominis, Chilomastix mesnili, Entamoeba hartmanni, Entamoeba coli and disperser, Strongyloides stercoralis

2. Blastocystis hominis, Endolimax nana, Entamoeba dispar, Hymenolepsis nana, Strongyloides stercoralis

3. Blastocystis hominis, Chilomastix mesnili, Entamoeba hartmanni, Entamoeba coli, Giardia, Hymenolepsis nana

4. Blastocystis hominis, Entamoeba coli, Endolimax nana, Entamoeba dispar, Ancylostoma, Giardia, Strongyloides stercoralis

5. Blastocystis hominis, Endolimax nana, Entamoeba dispar, Dientamoeba fragilis, Giardia, Hymenolepsis nana

6. Blastocystis hominis, Chilomastix mesnili, Endolimax nana, Entamoeba dispar, Ancylostoma, Giardia, Strongyloides stercoralis

7. Blastocystis hominis, Chilomastix mesnili, Entamoeba histolytica/dispar, Dientamoeba fragilis, Giardia, Hymenolepsis nana

8. Blastocystis hominis, Ascaris, Dientamoeba fragilis

Table 2 Laboratory screening

	Positive Test for SS N=18	Negative Test for SS N=218
Iron saturation	12/16 (75.0)	113/154 (73.4)
≤0.20; N (%)	0.11 ± 0.05	0.13 ± 0.05
Average ± SD	0.11 [0.01-0.18]	0.14 [0.02-0.20]
Eosinophilia	14 (77.8)	24/216 (11.1)
≥500 cells/mm ³ ; N (%)	1853.9 ± 893.1	1043.8 ± 792.4
Average ± SD	1800 [600-3800]	700 [600-3600]
TST (PPD)	3/12 (25.0)	78/180 (43.3)
≥10mm; N (%)	15.0 ± 3.5	17.4 ± 6.6
Average ± SD	13.0 [13-19]	15.0 [10-40]
Hepatitis B	0	2/216 (0.9)
HBsAg; N (%)	4 (22.2)	96/213 (45.1)
Anti-HBs ≥ 10 mU/ml; N (%)	1/17 (5.9)	3/199 (1.5)
Anti-HBc (Ig G); N (%)	0	1/3
Anti-HBc (Ig M); N (%)		
Hepatitis C (Anti-HCV Ig G); N (%)	0/16	0/215
Syphilis (RPR); N (%)	0	0
HIV (Elisa); N (%)	0/17	0/213
Stool parasites		
Infection with ≥1 pathogen/commensal; N (%)	13/15 (86.7)	84/180 (46.6)
Infection with ≥3 pathogens/commensals; N (%)	8/15 (53.3)	34/180 (18.8)
Infection with ≥1 pathogen; N (%)	12/15 (80.0)	47/180 (26.1)
Bacterial stool cultures; N (%)	2/10 (20.0)	4/59 (6.8)

Table 4 Univariate and multivariate analysis for positive test for SS

N total = 236	Crude OR (95% CI)	Adjusted * OR (95% CI)
Female	2.4 [0.8 - 7.0]	-
Age ≤ 5 years	4.4 [1.4 - 13.9]	-
Haïti	11.8 [2.7 - 52.7]	3.6 [0.7 - 19.1]
Weight < 5% Percentile	2.4 [0.8 - 7.2]	-
Iron Saturation ≤ 0.20	1.1 [0.3 - 3.6]	-
Eosinophilia ≥ 500/mm ³	28.0 [8.5 - 92.0]	13.6 [3.8 - 49.4]
TST (PPD) ≥ 10mm	0.9 [0.7 - 1.2]	-
Stool parasites		
Infection with ≥1 pathogen/commensal	4.1 [1.4 - 12.0]	-
Infection with ≥3 pathogens/commensals	4.3 [1.6 - 11.7]	-
Infection with ≥1 pathogen	7.2 [2.6 - 20.3]	2.6 [0.8 - 8.7]
Bacterial stool cultures	6.7 [1.1 - 39.3]	-

* Adjusted in the model for country of origin, eosinophilia and infection with pathogenic parasite